Brief: Sirnaomics Receives "Safe To Proceed" Letter From U.S. FDA For Investigational New Drug Application
16/02/2022 09:00
Feb 16 (Reuters) - Sirnaomics Ltd 2257.HK :
* RECEIVED "SAFE TO PROCEED" LETTER FROM U.S. FDA FOR
INVESTIGATIONAL NEW DRUG APPLICATION FOR SYSTEMIC RNAI
THERAPEUTIC STP707
* PHASE I CLINICAL TRIAL EXPECTED TO INITIATE IN Q2 2022
Source text for Eikon: ID:
Further company coverage: 2257.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million